津药药业：子公司药品复合磷酸氢钾注射液通过仿制药一致性评价

Group 1 - The core point of the article is that Tianyao Pharmaceutical (600488) announced the approval of its subsidiary Tianyao Heping for the injection of compound potassium hydrogen phosphate by the National Medical Products Administration, indicating that the product has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2 - The approval signifies a significant milestone for the company, enhancing its product portfolio in the pharmaceutical market [1] - The successful completion of the consistency evaluation may lead to increased market competitiveness and potential revenue growth for the company [1] - This development reflects the ongoing regulatory support for generic drugs in the industry, which may encourage further investments and innovations [1]